GLP1R and type 2 diabetes mellitus: Tirzepatide, a dual GLP-1 and GIP receptor agonist, has demonstrated significant renal protective effects in patients with type 2 diabetes and high cardiovascular risk, including reduced albuminuria, slower decline in eGFR, and a lower incidence of composite kidney outcomes [113].